Symbicort Product information
Therapeutic indications & presentation
Symbicort® (budesonide/formoterol) is indicated for adults, adolescents 12 years and older and children aged 6 years and older (100/6 Turbohaler only)1 for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting ß2-adrenoceptor agonist) is appropriate.1-4
- Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting ß2-adrenoceptor agonists or
- Patients already adequately controlled on both inhaled corticosteroids and long acting ß2-adrenoceptor agonists.
Symbicort Turbohaler 400/12 should be used as Maintenance Therapy only. Lower strengths are available for the Symbicort Maintenance and Reliever Therapy regimen (100mcg/6mcg/inhalation Turbohaler, 200mcg/6mcg/inhalation Turbohaler and 100mcg/3mcg/inhalation pMDI).1-4
Symbicort 100/3 pMDI is to be used in the treatment of asthma and is not approved in the UK for the treatment of COPD.4
Please note that an alternative strength of Symbicort pMDI is also available (200/6 mcg/inhalation). Symbicort 200/6 pMDI is to be used in the treatment for COPD and is not approved in the UK for the treatment of asthma.5